Skip to the answer

Belatacept Injection Uses, Dosage, Side Effects and Interactions

Brand name
Nulojix

Nulojix was the first belatacept injection product the FDA approved, in 2011.

Belatacept Injection (Nulojix) is an intravenous immune-suppressing medicine used to help prevent organ rejection in adults who have had a kidney transplant.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Belatacept InjectionType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Belatacept Injection in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Belatacept (Nulojix) is an IV anti-rejection medicine for adult kidney transplant recipients that blocks a signal T cells need to attack the new organ; on the market since about 2011, with no generic version, it is a specialist alternative to tacrolimus, sometimes chosen because it can be easier on the kidney long term. Most people handle the infusions well, noticing mainly diarrhea or constipation, leg swelling, and urinary tract infections. Its boxed warning covers PTLD (a lymphoma that often involves the brain), other cancers and serious infections, so it is only for people already exposed to Epstein-Barr virus.

Key Takeaways From the HelloPharmacist Team

  • Expect a 30-minute IV infusion at a clinic, frequent in the first months, then about every 4 weeks, so keep every appointment.
  • Report new confusion, memory or behavior changes, or weakness to your transplant team immediately; they can signal PTLD or a rare brain infection.
  • Treat fever, chills, cough or burning with urination as urgent, and keep taking the preventive infection medicines your team prescribes.
  • Use high-SPF sunscreen and protective clothing, and show your team any new skin lump or changing spot, since skin cancer risk rises.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Belatacept Injection.

Nulojix raises the risk of post-transplant lymphoproliferative disorder (PTLD), a type of lymphoma that mostly affects the brain and nervous system. The risk is highest in people who have never been exposed to Epstein-Barr virus (EBV). For that reason, it must only be used in EBV-positive patients.

It also raises the risk of serious infections and other cancers because it suppresses the immune system. It is not recommended for liver transplant patients because of a higher risk of graft loss and death. Only doctors experienced in transplant immunosuppression should prescribe it. Watch for new or worsening confusion, memory or behavior changes, weakness, or signs of infection, and report them right away.

Read the full warning on DailyMed →

Belatacept Injection by the Numbers

Strengths
1
in one form
Makers and packagers
1
Earliest FDA record
2011
Rank by Medicaid prescriptions
#958 of 1,682 drugs
More prescriptions than 43% of the 1,682 drugs we measure
10,001 prescriptions, Q1–Q4 2025

Patient Information Guide for Belatacept Injection

What It’s Used For

Belatacept Injection is used to help prevent rejection of a transplanted kidney.

  • Nulojix (intravenous) is used for prophylaxis of organ rejection in adults receiving a kidney transplant.
  • It is used together with basiliximab induction, mycophenolate mofetil, and corticosteroids.
  • It is for EBV-positive patients only.
  • Use in other transplanted organs has not been established.

How It Works

Belatacept is a selective T cell costimulation blocker. It binds to proteins called CD80 and CD86 on immune cells that present antigens. This blocks a signal (through CD28) that T cells need to become active.

Activated T cells are the main drivers of organ rejection, so blocking this signal helps protect the transplanted kidney.

Drug Class

Drug Class

  • Selective T Cell Costimulation Blocker
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Selective T Cell Costimulation Blocker

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • CD80-directed Antibody Interactions
  • CD86-directed Antibody Interactions

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)
  • T Lymphocyte Costimulation Activity Blockade

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Belatacept Injection in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Selective immunosuppressants

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Nulojix is given only as an IV infusion over about 30 minutes, in a healthcare setting.

  • Doses are more frequent in the first few months after transplant.
  • After that, infusions are about every 4 weeks.
  • Doses are based on your body weight at the time of transplant.
  • Food does not matter, since it is not taken by mouth.

If you miss an appointment, contact your transplant team promptly to reschedule.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Preventing rejection of a transplanted kidney

Adults receiving a kidney transplant · Day 1 and Day 5 Starting dose 10 mg per kg
Adults receiving a kidney transplant · End of Week 2 and Week 4 Usual dose 10 mg per kg
Adults receiving a kidney transplant · End of Week 8 and Week 12 Usual dose 10 mg per kg
Adults receiving a kidney transplant · End of Week 16 onward Usual dose 5 mg per kg

Good to Know for Every Dose

Dose based on actual body weight at time of transplantation; must be evenly divisible by 12.5 mg

See the Full Dosing Instructions on DailyMed →

Side Effects

The most common side effects in clinical trials included:

Common side effects

  • Anemia (low red blood cell count)
  • Diarrhea
  • Urinary tract infection
  • Swelling in the legs or feet (peripheral edema)
  • Constipation
  • High blood pressure
  • Fever
  • Cough
  • Nausea and vomiting
  • Headache
  • Low or high potassium
  • Low white blood cell count

When to get medical help

  • Call your doctor right away if you have new or worsening confusion, memory problems, behavior changes, weakness, or other neurological symptoms. These can signal PTLD or PML.
  • Get medical help for signs of infection, such as fever, chills, cough, or burning with urination. Serious infections, including tuberculosis, can happen and some have been fatal.
  • Report any new skin changes or lumps. Immune-suppressing medicines raise the risk of cancers, including skin cancer.
  • Tell your transplant team about any decrease in kidney function or other signs your transplant may not be working well.

The most serious reactions are PTLD, other cancers, and serious infections including PML and BK virus kidney infection. Call your doctor right away for neurological changes or signs of infection.

Warnings and Precautions

  • PTLD: A lymphoma risk, mainly in the brain, highest in people without prior EBV exposure.
  • Serious infections: Includes tuberculosis, CMV, herpes, fungal infections, PML, and BK virus kidney infection. Some were fatal.
  • Other cancers: Including skin cancer. Limit sun and UV exposure.
  • Liver transplant: Not recommended.
  • Steroid reduction: Too little corticosteroid has been linked to more rejection.
  • Switching from CNI regimens: Increases rejection risk unless you cannot tolerate CNIs.
  • Vaccines: Avoid live vaccines.

Interactions

Several medicines and situations need extra care with Nulojix.

  • Mycophenolate mofetil: dose may need adjusting when switching between cyclosporine and Nulojix, because levels of its active form change.
  • Anti-thymocyte globulin: given at the same time as the first dose, it may raise the risk of a clot in the transplanted kidney's vein.
  • Live vaccines: avoid them while on treatment.
  • Drugs processed by common liver enzymes: no dose changes needed.

Interactions Listed in the FDA-Approved Label

From the Belatacept Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Mycophenolate mofetil (MMF)
    What happensCyclosporine decreases mycophenolic acid (MPA) exposure while NULOJIX does not, so switching between them changes MPA levels.
    What to doMonitor for a need to adjust MMF dosage when switching between cyclosporine and NULOJIX; a higher MMF dosage may be needed after switching to cyclosporine, a lower one after switching to NULOJIX.
  • Cytochrome P450 substrates (CYP1A2, CYP2C9, CYP2D6, CYP3A, CYP2C19)
    What happensNo clinically important interaction is stated for drugs metabolized via these enzymes.
    What to doNo dosage adjustments are needed.
  • Anti-thymocyte globulin (or any other cell-depleting induction treatment)
    What happensCoadministration at the same or nearly the same time may pose a risk for venous thrombosis of the renal allograft in de novo kidney transplant recipients, especially those with other risk factors.
Read the label’s full interactions text

7 DRUG INTERACTIONS 7.1 Mycophenolate Mofetil (MMF) Monitor for a need to adjust concomitant mycophenolate mofetil (MMF) dosage when a patient’s therapy is switched between cyclosporine and NULOJIX, as cyclosporine decreases mycophenolic acid (MPA) exposure by preventing enterohepatic recirculation of MPA while NULOJIX does not: • A higher MMF dosage may be needed after switching from NULOJIX to cyclosporine, since this may result in lower MPA concentrations and increase the risk of graft rejection. • A lower MMF dosage may be needed after switching from cyclosporine to NULOJIX, since this may result in higher MPA concentrations and increase the risk for adverse reactions related to MPA (review the Full Prescribing Information for MMF). 7.2 Cytochrome P450 Substrates No dosage adjustments are needed for drugs metabolized via CYP1A2, CYP2C9, CYP2D6, CYP3A, and CYP2C19 when coadministered with NULOJIX. 7.3 Anti-Thymocyte Globulin Coadministration (at the same or nearly the same time) of anti-thymocyte globulin (or any other cell-depleting induction treatment) and belatacept in de novo kidney transplant recipients, especially those with other predisposing risk factors for venous thrombosis of the renal allograft, may pose a risk for venous thrombosis of the renal allograft.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Must be EBV positive. Not for EBV-negative people or those with unknown EBV status.
  • Not recommended for liver transplant.
  • Needs TB testing, and treatment of latent TB, before starting.
  • Pregnancy: may cause fetal harm based on animal data; a pregnancy registry is available.
  • Breastfeeding: unknown whether it passes into milk; discuss with your doctor.
  • Under 18: not established.
  • Older adults: no overall differences seen, but greater sensitivity cannot be ruled out.

Overdose

Single doses up to 20 mg per kg were given to healthy people without apparent toxic effect. Higher and more frequent dosing than recommended in kidney transplant patients led to more nervous-system-related side effects. If an overdose happens, you should be monitored for side effects and treated for any symptoms.

Half-Life and How Your Body Processes It

Belatacept is given by IV, so it enters the bloodstream directly. Its half-life is about 8 to 10 days, and levels reach steady state by about Week 8 early after transplant and by Month 6 during maintenance. Clearance tends to be higher with increasing body weight. Age, sex, race, kidney function, liver function, and diabetes did not affect clearance.

Storage

NULOJIX lyophilized powder is stored refrigerated at 2°C to 8°C (36°F to 46°F). Storing in the original package until time of use. Stored under refrigeration conditions: 2°C to 8°C (36°F to 46°F) and protected from light for up to 24 hours (a maximum of 4 hours of the total 24 ho…

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Belatacept Injection: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Belatacept Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What is Nulojix used for?

Nulojix helps prevent your body from rejecting a transplanted kidney. It is for adults and is used along with other anti-rejection medicines: basiliximab, mycophenolate mofetil, and corticosteroids. It is only for people who have been exposed to the Epstein-Barr virus.

How is Nulojix given?

It is given through an IV over about 30 minutes by a healthcare professional. You get it more often in the first few months after your transplant, then about every 4 weeks. Your dose is based on your weight, so follow your transplant team's schedule.

What happens if I miss a Nulojix infusion?

Call your transplant team as soon as you can to reschedule. Don't wait until your next appointment, since staying on schedule helps protect your new kidney. Your team will tell you how to get back on track.

What side effects should I expect?

Common ones include anemia, diarrhea, urinary tract infections, swelling in the legs, constipation, high blood pressure, fever, cough, nausea, vomiting, and headache. Call your doctor right away for confusion, memory or behavior changes, weakness, or signs of infection, since these can be serious.

Can I get vaccines while on Nulojix?

Avoid live vaccines while you are being treated. Examples include intranasal flu, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and typhoid (TY21a). Check with your transplant team before any vaccine.

Is Nulojix safe during pregnancy or breastfeeding?

Based on animal data, it may cause fetal harm, and there isn't enough human data to be sure. It's not known whether it passes into breast milk. Talk with your doctor before pregnancy or breastfeeding so you can weigh the benefits and risks.

Is belatacept injection available over the counter?

No. Belatacept injection is a prescription medicine: every belatacept injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was belatacept injection first available?

The earliest FDA record we hold for belatacept injection is from 2011: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when belatacept injection was first used.

What is the brand name of belatacept injection?

Belatacept injection is the generic name. Its brand name is Nulojix.

What is the generic name of Nulojix?

The generic name of Nulojix is belatacept injection. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is belatacept injection?

Belatacept injection belongs to the drug class Selective T Cell Costimulation Blocker, its established pharmacologic class on the FDA label. The FDA also groups it by how it works: CD80-directed Antibody Interactions and CD86-directed Antibody Interactions.

What strengths does belatacept injection come in?

Belatacept injection is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein): 250 mg. A listing does not mean every pharmacy stocks every strength.

Where can I read the belatacept injection prescribing information (package insert)?

The full FDA-approved prescribing information for belatacept injection, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from E.R. Squibb & Sons, L.L.C.'s, revised Jul 28, 2021, and links to it on DailyMed.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Belatacept Injection

Skip the scrolling. Ask in your own words and get an answer from Belatacept Injection’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Belatacept Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Belatacept Injection on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, usually within a day.
Detailed Data & References for Belatacept Injection Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Belatacept Injection Forms and Strengths (How It Comes)

Belatacept Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Belatacept Injection inactive ingredients by manufacturer.

Injection

Into a vein
Brands Nulojix (the first brand, 2011)
How this form is used
What it may be used for
  • Nulojix is used to help prevent organ rejection in adults receiving a kidney transplant.
  • Nulojix is used with basiliximab induction, mycophenolate mofetil, and corticosteroids.
Important instructions
  • Nulojix is given by intravenous infusion only, over about 30 minutes.
  • Nulojix powder is mixed and diluted by a healthcare professional using the silicone-free syringe supplied with each vial.
  • Nulojix should be infused in a separate IV line from other medicines.
  • Nulojix dosing is based on body weight and should not be higher or more frequent than recommended.
Available strengths 1 strength
1 FDA-listed product record ⓘ

Belatacept Injection on the U.S. Market: Products, Makers and Brands

How Belatacept Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 1 Belatacept Injection product record with the FDA, mostly as injection; the earliest marketing or approval year on record is 2011. The one brand name in the directory today is Nulojix; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
1
FDA-listed product records ⓘ
2011
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Unfinished injection, powder, lyophilized, for solution (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

How Widely Belatacept Injection Is Used (Medicaid Data)

How many Belatacept Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

10,001
Medicaid prescriptions filled (Q1–Q4 2025)
$10.7M paid by Medicaid, before rebates

How commonly is Belatacept Injection prescribed? Of the 1,682 medications we measure, Belatacept Injection ranks #958 by Medicaid prescriptions — more than 43% of them.

Where Belatacept Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Belatacept Injection product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

belatacept 250 MG Injection

10,001 Medicaid prescriptions (Q1–Q4 2025) 100% of Belatacept Injection prescriptions shown $10.7M paid by Medicaid, before rebates ≈ $1,068 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 1112976

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 1 of the 1 listed Belatacept Injection NDCs had Medicaid claims.

Compare Belatacept Injection Products

A representative set of FDA-listed product records for Belatacept Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
250 mg Intravenous E.R. Squibb & Sons, L.L.C. BLA View NDC →

Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Belatacept Injection NDCs →

Belatacept Injection Side Effects Reported to the FDA (FAERS)

After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Belatacept Injection — a signal of what to watch for, not proof the drug caused it.

The effects most often named in FDA reports that mention Belatacept Injection are death, transplant rejection, kidney transplant rejection; about 76% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.

4,739
Reports mentioning it
76%
Reported as serious
12
Distinct effects shown
Most reported effects
Death
232
Transplant Rejection
231
Kidney Transplant Rejection
222
Cytomegalovirus Infection
179
Acute Kidney Injury
178
Product Storage Error
177
Covid-19
149
Hospitalisation
128
Pyrexia
117
Thrombotic Microangiopathy
105
Age groups
Adult · 644Elderly · 284Neonate · 11Adolescent · 10Child · 2Infant · 1

Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Belatacept Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.

Belatacept Injection FDA Approval History

How Belatacept Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.

Belatacept Injection was first approved by the FDA in 2011 (Brand: NULOJIX · Bristol Myers Squibb). It remains available in U.S. pharmacies today.

2011
Brand approved
Brand: NULOJIX · Bristol Myers Squibb
2026
Available today
Active in U.S. pharmacies

Source: Drugs@FDA.

Belatacept Injection Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Belatacept recalls since July 2021.

✅No Belatacept recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Belatacept Injection in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
1
Strengths
1
Forms in current FDA listings
1 of 1
In current FDA listings No current FDA listing
Ingredient (IN) Belatacept Injection RxCUI 1112973
  1. Dose form (SCDF) Injection RxCUI 1804971
    In current FDA listings
    Its strength (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Belatacept Injection Brand Names

Belatacept Injection has one brand name on record: Nulojix. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Nulojix the first brand, 2011

Who Makes Belatacept Injection: Manufacturers and Labelers

One company lists Belatacept Injection products with the FDA. By number of product records, the largest are E.R. Squibb & Sons, L.L.C.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

E.R. Squibb & Sons, L.L.C. 1

Sources for This Belatacept Injection Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jul 28, 2021, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Belatacept Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
1
Finished products in the current FDA directory
1
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
E.R. Squibb & Sons, L.L.C.
Linked label effective
Jul 28, 2021
Composite sections available
24
Linked SPL Set ID
c16ac648-d5d2-9f7d-8637-e2328572754e
Linked SPL Document ID
9057087d-7e59-4e5a-8e4a-96a532efb0ab
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. E.R. Squibb & Sons, L.L.C. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →